Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-26
2011-10-25
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S362500
Reexamination Certificate
active
08044083
ABSTRACT:
The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases.
REFERENCES:
patent: 3755332 (1973-08-01), Wasley et al.
patent: 4571255 (1986-02-01), Nielsen
patent: 4997844 (1991-03-01), Bernstein et al.
patent: 5234942 (1993-08-01), Bernstein et al.
patent: 5587392 (1996-12-01), Murakami et al.
patent: 5616537 (1997-04-01), Yokota et al.
patent: 5932570 (1999-08-01), Rodgers et al.
patent: 5945418 (1999-08-01), Bemis et al.
patent: 6080763 (2000-06-01), Regan et al.
patent: 6083949 (2000-07-01), Liverton et al.
patent: 6093742 (2000-07-01), Salituro et al.
patent: 6194439 (2001-02-01), Dow
patent: 6214830 (2001-04-01), Beers et al.
patent: 6218386 (2001-04-01), Rodgers et al.
patent: 6228881 (2001-05-01), Regan et al.
patent: 6242453 (2001-06-01), Cirillo et al.
patent: 6297239 (2001-10-01), deSolms et al.
patent: 6297381 (2001-10-01), Cirillo et al.
patent: 6319921 (2001-11-01), Cirillo et al.
patent: 6329412 (2001-12-01), Goldstein et al.
patent: 6355636 (2002-03-01), Wissner et al.
patent: 6358945 (2002-03-01), Breitfelder et al.
patent: 6432995 (2002-08-01), Hickey
patent: 6479507 (2002-11-01), Cheng et al.
patent: 6503930 (2003-01-01), Hanson et al.
patent: 6509357 (2003-01-01), Zhou et al.
patent: 6531491 (2003-03-01), Kania et al.
patent: 6589954 (2003-07-01), Mavunkel et al.
patent: 6608058 (2003-08-01), Yoon et al.
patent: 6696464 (2004-02-01), McClure et al.
patent: 6716978 (2004-04-01), Marfat
patent: 6743795 (2004-06-01), Yoon et al.
patent: 6821966 (2004-11-01), Dugar et al.
patent: 6825184 (2004-11-01), Cirillo et al.
patent: 6858638 (2005-02-01), Damour et al.
patent: 6894173 (2005-05-01), Zhang et al.
patent: 6949579 (2005-09-01), Dutruc-Rosset et al.
patent: 7041669 (2006-05-01), Cirillo et al.
patent: 7102009 (2006-09-01), Patel et al.
patent: 7105682 (2006-09-01), Chen et al.
patent: 7129252 (2006-10-01), Chen
patent: 7135575 (2006-11-01), Munson et al.
patent: 7166629 (2007-01-01), Lesuisse et al.
patent: 7196082 (2007-03-01), Doherty et al.
patent: 7199147 (2007-04-01), Imazaki et al.
patent: 7414132 (2008-08-01), De La Torre et al.
patent: 7511136 (2009-03-01), Amici et al.
patent: 7521447 (2009-04-01), Munson et al.
patent: 7589112 (2009-09-01), Buchstaller et al.
patent: 7655802 (2010-02-01), Schumacher et al.
patent: 7737153 (2010-06-01), Feurer et al.
patent: 2003/0220241 (2003-11-01), Defeo-Jones et al.
patent: 2004/0180896 (2004-09-01), Munson et al.
patent: 2004/0192653 (2004-09-01), Munson et al.
patent: 2004/0192654 (2004-09-01), Gourdeau et al.
patent: 2006/0241127 (2006-10-01), Feurer et al.
patent: 2006/0264431 (2006-11-01), Munson et al.
patent: 2009/0023795 (2009-01-01), Groneberg et al.
patent: 2009/0048301 (2009-02-01), Chen et al.
patent: 2009/0143422 (2009-06-01), Munson et al.
patent: 1235602 (1999-11-01), None
patent: 200000385 (2000-10-01), None
patent: 200000488 (2000-10-01), None
patent: 002113 (2001-12-01), None
patent: 0293978 (1988-12-01), None
patent: 0448206 (1991-09-01), None
patent: 0684235 (1995-11-01), None
patent: 1403255 (2004-03-01), None
patent: 59098060 (1984-06-01), None
patent: 63068568 (1988-03-01), None
patent: 2004129780 (2005-04-01), None
patent: 2004130280 (2005-06-01), None
patent: 2005104820 (2005-10-01), None
patent: 2005109561 (2005-11-01), None
patent: 1545940 (1990-02-01), None
patent: 1595338 (1990-09-01), None
patent: 92/021660 (1992-12-01), None
patent: WO 97/12876 (1997-04-01), None
patent: 98/009961 (1998-03-01), None
patent: 98/013350 (1998-04-01), None
patent: 98/020008 (1998-05-01), None
patent: 98/043960 (1998-10-01), None
patent: WO 99/17777 (1999-04-01), None
patent: 99/023076 (1999-05-01), None
patent: 99/023077 (1999-05-01), None
patent: WO 00/17170 (2000-03-01), None
patent: WO 00/43384 (2000-07-01), None
patent: WO 00/59930 (2000-10-01), None
patent: 00/66583 (2000-11-01), None
patent: WO 00/71535 (2000-11-01), None
patent: WO 01/02369 (2001-01-01), None
patent: WO 01/38306 (2001-05-01), None
patent: WO 01/78648 (2001-10-01), None
patent: WO 02/42292 (2002-05-01), None
patent: 02/059088 (2002-08-01), None
patent: WO 02/068406 (2002-09-01), None
patent: WO 02/072579 (2002-09-01), None
patent: WO 02/100833 (2002-12-01), None
patent: WO 03/032989 (2003-03-01), None
patent: 03/028720 (2003-04-01), None
patent: WO 03/032989 (2003-04-01), None
patent: WO 03/051847 (2003-06-01), None
patent: WO 03/072569 (2003-09-01), None
patent: WO 03/087072 (2003-10-01), None
patent: 04/009557 (2004-01-01), None
patent: WO 2004/007481 (2004-01-01), None
patent: WO 2004/037789 (2004-05-01), None
patent: WO 2004/039796 (2004-05-01), None
patent: WO 2004/052280 (2004-06-01), None
patent: WO 2004/078116 (2004-09-01), None
patent: 2004/100946 (2004-11-01), None
patent: WO 2004/113303 (2004-12-01), None
patent: WO 2005/000232 (2005-01-01), None
patent: WO 2005/004818 (2005-01-01), None
patent: 2005023761 (2005-03-01), None
patent: WO 2005/023761 (2005-03-01), None
patent: 2005/063715 (2005-07-01), None
patent: WO 2005/066164 (2005-07-01), None
patent: WO 2007/089646 (2007-08-01), None
Aleshin, Alexey et al., “Myocardial Protective Effect of FR167653: A Novel Cytokine Inhibitor in Ischemic-Reperfused Rat Heart”,European Journal of Cardio-Thoracic Surgery, 26(5), 974-980, (2004).
Badger, Alison M. et al., “Disease-Modifying Activity of SB 242235, a Selective Inhibitor of p38 Mitogen-Activated Protein Kinase, in Rat Adjuvant-Induced Arthritis”,Arthritis&Rheumatism, 43(1), 175-183, (2000).
Badger, Alison M. et al., “Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function”,Journal of Pharmacology and Experimental Therapeutics, 279(3), 1453-1461, (1996).
Birkenkamp, K.U. et al., “Differential Effects of Interleukin-3 and Interleukin-1 on the Proliferation and Interleukin-6 Protein Secretion of Acute Myeloid Leukemic Cells; The involvement of ERK, p38 and STAT5”,European Cytokine Network, 10(4), 479-490, (1999).
Branger, Judith et al., “Inhibition of Coagulation, Fibrinolysis and Endothelial Cell Activation by a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia”,Blood, 101(11), 4446-4448, (2003).
Brown, Kimberly K. et al., “P38 MAP Kinase Inhibitors as Potential Therapeutics for the Treatment of Joint Degeneration and Pain Associated with Osteoarthritis”,Journal of Inflammation, 5(22), 8 pages, (2008).
Cau, Jerome, et al., “FR167653 Improves Renal Recovery and Decreases Inflammation and Fibrosis After Renal Ischemia Reperfusion Injury”,Journal for Vascular Surgery, 49(3), 728-740, (2009).
Chen, Xu-Lin et al., “Role of p38 Mitogen-Activated Protein Kinase in Lung Injury after Burn Trauma”,Shock, 19(5), 475-479, (2003).
Clark, James E. et al., “Potential of p38-MAPK Inhibitors in the Treatment of Ischaemic Heart Disease”,Pharmacology and Therapeutics, 116, 192-206, (2007).
Cottrell, Jessica A. et al., “Analgesic Effects of p38 Kinase Inhibitor Treatment on Bone Fracture Healing”,PAIN, 142(1-2), 116-126, (2009).
Denkert, Carsten et al., “An Inhibitor of Stress-Activated MAP-Kinases Reduces Invasion and MMP-2 Expression of Malignant Melanoma Cells”,Clinical and Experimental Metastasis, 19, 79-85, (2002).
Doucet, Carole et al., “A p38 Mitogen-Activated Protein Kinase Inhibitor Protects Against Renal Damage in a Non-Heart-Beating Donor Model”,American Journal of Physiology—Renal Physiology, 295(1), F179-191, (2008).
Duan, Wei et al., “Inhaled p38a Mitogen-Activated Protein Kinase Antisense Oligonucleotide Attenuates Asthma in Mice”,Am. J. Respir. Crit. Care Med., 171, 571-578, (2005).
Fijen, J.W. et al., “Suppression of the Clinical Cytokine Response to Endotoxin by RWJ-67657, a p38 Mitogen-Activated Protein-Kinase Inhibitor, in Healthy Human Volunteers”,Clin
Burgess Laurence E.
Eary Charles Todd
Groneberg Robert
Harvey Darren
Laird Ellen
Anderson Rebecca L
Array BioPharma Inc.
Mastous Sarah S.
Moore, Esq. John R.
LandOfFree
Kinase inhibitors and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kinase inhibitors and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kinase inhibitors and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4267808